

Chang-Ki Min

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3324583/publications.pdf>

Version: 2024-02-01

213
papers

3,032
citations

236925

25
h-index

254184

43
g-index

216
all docs

216
docs citations

216
times ranked

4287
citing authors

#	ARTICLE	IF	CITATIONS
1	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 2096-2107.	13.7	435
2	The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome α positive acute lymphoblastic leukemia. <i>Blood</i> , 2005, 105, 3449-3457.	1.4	177
3	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	6.2	126
4	Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 704-717.	2.0	69
5	Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. <i>Haematologica</i> , 2019, 104, 269-276.	3.5	67
6	Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro α inflammatory cytokines. <i>European Journal of Haematology</i> , 2006, 76, 265-268.	2.2	53
7	The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. <i>The Korean Journal of Hematology</i> , 2011, 46, 80.	0.7	45
8	Alteration of the Intestinal Microbiota by Broad-Spectrum Antibiotic Use Correlates with the Occurrence of Intestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1933-1943.	2.0	42
9	Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. <i>Annals of Hematology</i> , 2015, 94, 445-452.	1.8	40
10	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	1.8	39
11	Pharmacokinetics and safety of ixazomib plus lenalidomide α dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. <i>Journal of Hematology and Oncology</i> , 2015, 8, 103.	17.0	37
12	A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 119-129.	2.0	36
13	Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy. <i>Annals of Hematology</i> , 2013, 92, 497-504.	1.8	34
14	Mesenchymal Stem Cells (MSCs) Attenuate α Cutaneous Sclerodermatous Graft-Versus-Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration in a Mouse Model. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1895-1904.	0.7	34
15	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , 2017, 92, 1280-1286.	4.1	34
16	Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma. <i>Maxillofacial Plastic and Reconstructive Surgery</i> , 2017, 39, 1.	1.8	33
17	Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2. <i>Experimental and Molecular Medicine</i> , 2014, 46, e121-e121.	7.7	31
18	WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1925-1932.	2.0	31

#	ARTICLE	IF	CITATIONS
19	Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor. <i>Blood</i> , 2016, 128, 1150-1150.	1.4	30
20	Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome. <i>Journal of Hematology and Oncology</i> , 2015, 8, 118.	17.0	29
21	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009, 122, 200-210.	1.4	28
22	Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 32-42.	2.0	28
23	Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2019, 125, 873-883.	4.1	28
24	Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission. <i>Oncotarget</i> , 2016, 7, 17230-17241.	1.8	28
25	Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts. <i>Oncotarget</i> , 2017, 8, 12342-12354.	1.8	27
26	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2021, 106, 1182-1187.	3.5	27
27	Graft-versus-Tumor Effect According to Type of Graft-versus-Host Disease Defined by National Institutes of Health Consensus Criteria and Associated Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1136-1143.	2.0	26
28	Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. <i>Journal of Clinical Virology</i> , 2015, 73, 64-69.	3.1	25
29	The therapeutic efficacy of mesenchymal stromal cells on experimental colitis was improved by the IFN- γ and poly(I:C) priming through promoting the expression of indoleamine 2,3-dioxygenase. <i>Stem Cell Research and Therapy</i> , 2021, 12, 37.	5.5	25
30	Feasible Outcomes of T Cell-Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 342-349.	2.0	23
31	Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia. <i>International Journal of Stem Cells</i> , 2019, 12, 73-83.	1.8	23
32	Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 471-478.e4.	1.2	22
33	Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 63-72.	2.0	22
34	Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. <i>Cancer Medicine</i> , 2019, 8, 6860-6870.	2.8	22
35	Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 983-994.	4.2	21
36	Hepatosplenic tuberculosis mimicking disseminated candidiasis in patients with acute leukemia. <i>International Journal of Hematology</i> , 2001, 73, 119-121.	1.6	20

#	ARTICLE	IF	CITATIONS
37	Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 627-634.	1.8	20
38	Bone Cement Augmentation Procedures for Spinal Pathologic Fractures by Multiple Myeloma. <i>Journal of Korean Medical Science</i> , 2015, 30, 88.	2.5	20
39	Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. <i>Korean Journal of Physiology and Pharmacology</i> , 2016, 20, 63.	1.2	20
40	Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 588-597.	2.0	20
41	Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. <i>Haematologica</i> , 2017, 102, e456-e459.	3.5	20
42	The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. <i>PLoS ONE</i> , 2017, 12, e0173250.	2.5	20
43	Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. , 2019, 7, 35.		20
44	Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma. <i>Immune Network</i> , 2017, 17, 250.	3.6	19
45	Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types. <i>Oncotarget</i> , 2017, 8, 41590-41604.	1.8	19
46	Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. <i>Annals of Hematology</i> , 2014, 93, 1353-1361.	1.8	18
47	Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study. <i>American Journal of Hematology</i> , 2021, 96, 98-109.	4.1	17
48	Wilms Tumor Gene 1 Expression as a Predictive Marker for Relapse and Survival after Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 460-467.	2.0	16
49	Induction of Indoleamine 2,3-dioxygenase by Pre-treatment with Poly(I:C) May Enhance the Efficacy of MSC Treatment in DSS-induced Colitis. <i>Immune Network</i> , 2016, 16, 358.	3.6	16
50	Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1498-1508.	2.0	16
51	Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia. <i>European Journal of Haematology</i> , 2017, 99, 336-343.	2.2	16
52	Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma. <i>Clinical Infectious Diseases</i> , 2021, 73, e1372-e1375.	5.8	16
53	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	1.8	16
54	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. <i>Haematologica</i> , 2022, 107, 1397-1409.	3.5	16

#	ARTICLE	IF	CITATIONS
55	Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma. <i>Cytotherapy</i> , 2012, 14, 505-512.	0.7	15
56	High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RAR α after anthracycline-based chemotherapy: a single-center cohort study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 30.	17.0	15
57	Clinical significance of pre-transplant circulating CD ³ ⁺ CD ⁴ ⁺ CD ¹⁶¹ ⁺ cell frequency on the occurrence of neutropenic infections after allogeneic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2017, 19, e12643.	1.7	15
58	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome with a Reduced Intensity Conditioning Regimen Consisting of Intravenous Busulfan, Fludarabine, and 400 Cgy Total Body Irradiation. <i>Blood</i> , 2009, 114, 4327-4327.	1.4	15
59	Supplemental peripheral blood stem cells to decrease marrow rejection in adult patients with severe aplastic anemia. <i>American Journal of Hematology</i> , 2002, 69, 15-22.	4.1	14
60	Fluctuations in pathogenic CD4 ⁺ T-cell subsets in a murine sclerodermatous model of chronic graft-versus-host disease. <i>Immunological Investigations</i> , 2014, 43, 41-53.	2.0	14
61	Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea—experience from 110 patients. <i>Annals of Hematology</i> , 2014, 93, 113-121.	1.8	14
62	CD161 ⁺ T Cells as Predictive Markers for Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 421-428.	2.0	14
63	Inhibition of indoleamine 2,3-dioxygenase by stereoisomers of 1-methyl tryptophan in an experimental graft-versus-tumor model. <i>Experimental Hematology</i> , 2014, 42, 862-866.e3.	0.4	13
64	The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. <i>Acta Haematologica</i> , 2018, 140, 146-156.	1.4	13
65	Improved survival outcomes and restoration of graft-versus-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. <i>Cancer Medicine</i> , 2019, 8, 501-514.	2.8	13
66	DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 2738-2738.	1.4	13
67	Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose. <i>American Journal of Hematology</i> , 2018, 93, 1368-1375.	4.1	12
68	Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2019, 9, 11935.	3.3	12
69	A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation. <i>International Journal of Hematology</i> , 2019, 110, 635-639.	1.6	12
70	Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 774.e1-774.e12.	1.2	12
71	Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. <i>British Journal of Haematology</i> , 2021, 193, 101-112.	2.5	12
72	Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 362.	1.7	12

#	ARTICLE	IF	CITATIONS
73	Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2012, 91, 439-448.	1.8	11
74	Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal <scp>AML</scp> and identification of high-risk subgroup using <scp><i>W</i></scp> <i>T1</i> expression in association with <scp><i>N</i></scp> <i>PM1</i> and <scp><i>FLT3</i></scp> <i>ITD</i> mutations. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 489-499.	2.8	11
75	Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients. <i>Thrombosis Research</i> , 2015, 136, 974-979.	1.7	11
76	Emphysematous osteomyelitis due to <i>Escherichia coli</i> in multiple myeloma. <i>Blood Research</i> , 2016, 51, 224.	1.3	11
77	Ex Vivo Generated Human Cord Blood Myeloid-Derived Suppressor Cells Attenuate Murine Chronic Graft-versus-Host Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2381-2396.	2.0	11
78	Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2018-2026.	2.0	11
79	Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells. <i>Experimental Hematology and Oncology</i> , 2020, 9, 22.	5.0	11
80	Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. <i>Bone Marrow Transplantation</i> , 2021, 56, 1603-1613.	2.4	11
81	Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells. <i>Cancer Immunology Research</i> , 2021, 9, 503-513.	3.4	11
82	Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin-like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 316-323.	2.0	10
83	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929.	2.0	10
84	Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2992-3000.	2.3	10
85	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 92-95.	1.3	10
86	Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma. <i>Cell Proliferation</i> , 2020, 53, e12819.	5.3	10
87	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	6.2	10
88	Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	9
89	Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 20-27.	2.8	9
90	Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. <i>Hematological Oncology</i> , 2017, 35, 17-24.	1.7	9

#	ARTICLE	IF	CITATIONS
91	Practical informativeness of short tandem repeat loci for chimerism analysis in hematopoietic stem cell transplantation. <i>Clinica Chimica Acta</i> , 2017, 468, 51-59.	1.1	9
92	CD1d is a novel cell-surface marker for human monocytic myeloid-derived suppressor cells with T cell suppression activity in peripheral blood after allogeneic hematopoietic stem cell transplantation. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 519-525.	2.1	9
93	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019, 109, 79-90.	1.6	9
94	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP). <i>Journal of Clinical Oncology</i> , 2019, 37, 1164-1171.	1.64	9
95	Stratification of de novo Adult Acute Myelogenous Leukemia with Adverse-Risk Karyotype: Can We Overcome the Worse Prognosis of Adverse-Risk Group Acute Myelogenous Leukemia with Hematopoietic Stem Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 80-88.	2.0	8
96	Neutrophil Gelatinase-Associated Lipocalin as a Biomarker of Renal Impairment in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 35-40.	0.4	8
97	Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. <i>BMC Cancer</i> , 2016, 16, 247.	2.6	8
98	Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 1270-1277.	2.4	8
99	A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1312-1319.	2.0	8
100	Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer Medicine</i> , 2019, 8, 7650-7659.	2.8	8
101	Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease. <i>Experimental Hematology</i> , 2021, 98, 36-46.e2.	0.4	8
102	Perivascular Cells and NADPH Oxidase Inhibition Partially Restore Hyperglycemia-Induced Alterations in Hematopoietic Stem Cell and Myeloid-Derived Suppressor Cell Populations in the Bone Marrow. <i>International Journal of Stem Cells</i> , 2019, 12, 63-72.	1.8	8
103	Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 809-819.	1.7	8
104	Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 797028.	2.8	8
105	A paradoxical pattern of indoleamine 2,3-dioxygenase expression in the colon tissues of patients with acute graft-versus-host disease. <i>Experimental Hematology</i> , 2014, 42, 734-740.	0.4	7
106	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. <i>Annals of Hematology</i> , 2016, 95, 603-611.	1.8	7
107	Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia. <i>Blood Research</i> , 2017, 52, 174.	1.3	7
108	Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma. <i>Clinica Chimica Acta</i> , 2018, 479, 7-13.	1.1	7

#	ARTICLE	IF	CITATIONS
109	Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis. <i>Advances in Therapy</i> , 2020, 37, 3404-3416.	2.9	7
110	CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model. <i>Stem Cell Research and Therapy</i> , 2020, 11, 254.	5.5	7
111	Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 828-840.	2.4	7
112	Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. <i>American Journal of Hematology</i> , 2021, 96, 1441-1449.	4.1	7
113	Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation. <i>Molecules and Cells</i> , 2015, 38, 966-974.	2.6	7
114	A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210816.	2.5	7
115	The role of regulatory T cells during the attenuation of graft-versus-leukemia activity following donor leukocyte infusion in mice. <i>Leukemia Research</i> , 2011, 35, 1549-1556.	0.8	6
116	Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. <i>Leukemia and Lymphoma</i> , 2016, 57, 1389-1397.	1.3	6
117	Escape from thymic deletion and anti-leukemic effects of T cells specific for hematopoietic cell-restricted antigen. <i>Nature Communications</i> , 2018, 9, 225.	12.8	6
118	Low frequency of CD3+CD4+CD161+ T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment. <i>Annals of Hematology</i> , 2018, 97, 2163-2171.	1.8	6
119	Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 330-333.	2.4	6
120	Reactivation and dynamics of cytomegalovirus and Epstein-Barr virus after rabbit antithymocyte globulin and cyclosporine for aplastic anemia. <i>European Journal of Haematology</i> , 2019, 103, 433-441.	2.2	6
121	Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1469-1472.	2.4	6
122	Predictive impact of circulating microRNA-193a-5p on early relapse after autologous stem cell transplantation in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, 518-523.	2.5	6
123	Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death. <i>Annals of Hematology</i> , 2020, 99, 973-982.	1.8	6
124	Prognosis Prediction in Initially Diagnosed Multiple Myeloma Patients Using Intravoxel Incoherent Motion-Diffusion Weighted Imaging and Multiecho Dixon Imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 491-501.	3.4	6
125	Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. <i>Annals of Hematology</i> , 2021, 100, 2051-2059.	1.8	6
126	Ongoing Phase 1a/1b Dose-Finding Study of CWP232291 (CWP291) in Relapsed or Refractory Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4501-4501.	1.4	6

#	ARTICLE	IF	CITATIONS
127	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , 2017, 8, 37605-37618.	1.8	6
128	Clinical Implications of Abnormal Cytogenetics at Diagnosis of Aplastic Anemia.. <i>Blood</i> , 2006, 108, 986-986.	1.4	6
129	Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial. <i>Blood</i> , 2020, 136, 30-31.	1.4	6
130	Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	5
131	<i>SOCS1</i> and <i>SOCS3</i> are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation. <i>Blood Research</i> , 2015, 50, 40.	1.3	5
132	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. <i>Cancer Medicine</i> , 2017, 6, 100-108.	2.8	5
133	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020, 99, 309-319.	1.8	5
134	Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. <i>British Journal of Haematology</i> , 2020, 188, 860-871.	2.5	5
135	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. <i>International Journal of Hematology</i> , 2020, 112, 84-95.	1.6	5
136	Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia. <i>Hla</i> , 2020, 96, 445-455.	0.6	5
137	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2714-2721.	1.3	5
138	The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 424-432.	1.7	5
139	Monitoring of BCR-ABL Transcript Levels after Discontinuation of Imatinib Therapy in Chronic Myelogenous Leukemia Patients Achieving Complete Cytogenetic Response.. <i>Blood</i> , 2004, 104, 4684-4684.	1.4	5
140	Association between left ventricular function and paraprotein type in patients with multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 459-468.	1.7	5
141	Pretreatment Serum Soluble Interleukin-2 Receptor Levels Predict the Response after Immunosuppressive Therapy of Aplastic Anemia.. <i>Blood</i> , 2004, 104, 4219-4219.	1.4	5
142	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	4
143	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. <i>Blood Research</i> , 2015, 50, 7.	1.3	4
144	Attenuation of Hepatic Graft-versus-host Disease in Allogeneic Recipients of MyD88-deficient Donor Bone Marrow. <i>Immune Network</i> , 2015, 15, 125.	3.6	4

#	ARTICLE	IF	CITATIONS
145	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. <i>Annals of Hematology</i> , 2016, 95, 911-919.	1.8	4
146	Characteristics and Survival Outcome Analysis of Extramedullary Involvement in Adult Patients With t(8;21) Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 38-45.e2.	0.4	4
147	Skewed Dendritic Cell Differentiation of MyD88-Deficient Donor Bone Marrow Cells, Instead of Massive Expansion as Myeloid-Derived Suppressor Cells, Aggravates GVHD. <i>Immune Network</i> , 2018, 18, e44.	3.6	4
148	Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 345-355.e7.	0.4	4
149	Non-Myeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies. <i>European Journal of Haematology</i> , 2020, 105, 387-398.	2.2	4
150	Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110437.	2.5	4
151	Comparable Outcomes Between Unrelated and Haploidentical Stem Cell Transplantation in Adult Patients With Severe Aplastic Anemia. <i>Transplantation</i> , 2021, 105, 1097-1105.	1.0	4
152	Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1621-1628.	2.0	3
153	Circulating CD3 ⁺ CD4 ⁺ CD161 ⁺ Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	3
154	Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1743-1753.	1.8	3
155	Increased Osteoblastic Activity Suppressed Proliferation of Multiple Myeloma Plasma Cells. <i>Spine</i> , 2019, 44, E384-E392.	2.0	3
156	HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072093693.	2.5	3
157	Successful prevention and screening strategies for COVID-19: focus on patients with haematologic diseases. <i>British Journal of Haematology</i> , 2020, 190, e33-e37.	2.5	3
158	Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1906-1914.	2.0	3
159	Poor prognosis in patients with diffuse large B cell lymphomas with bone marrow involvement possessing chromosomal abnormalities, despite aggressive treatment. <i>Annals of Hematology</i> , 2020, 99, 557-570.	1.8	3
160	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021, 113, 81-91.	1.6	3
161	Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110205.	2.5	3
162	Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11. <i>Bone Marrow Transplantation</i> , 2021, 56, 2682-2689.	2.4	3

#	ARTICLE	IF	CITATIONS
163	Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. <i>International Journal of Hematology</i> , 2021, 114, 653-663.	1.6	3
164	Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. <i>Blood</i> , 2019, 134, 1893-1893.	1.4	3
165	Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial. <i>Blood</i> , 2015, 126, 4240-4240.	1.4	3
166	Prediction and recommendation by machine learning through repetitive internal validation for hepatic veno-occlusive disease/sinusoidal obstruction syndrome and early death after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	3
167	Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210767.	2.5	3
168	Fragmented Red Cell as a Possible Favorable Prognostic Marker of Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy. <i>Journal of Clinical Laboratory Analysis</i> , 2015, 29, 444-450.	2.1	2
169	Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 595-603.	0.4	2
170	Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e167-e182.	0.4	2
171	Cutaneous comorbidities in patients with multiple myeloma. <i>Medicine (United States)</i> , 2018, 97, e12825.	1.0	2
172	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2051-2059.	2.4	2
173	Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e97-e104.	0.4	2
174	Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072093203.	2.5	2
175	Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092104.	2.5	2
176	Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1â€“RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1â€“RUNX1T1. <i>Cancers</i> , 2021, 13, 336.	3.7	2
177	Enhancement of Graft-versus-leukemia Effects by Mesenchymal Stem Cells in Mixed Chimerism after a Murine Non-myeloablative Hematopoietic Stem Cell Transplantation. <i>The Korean Journal of Hematology</i> , 2008, 43, 219.	0.7	2
178	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 675-683.	1.7	2
179	Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110661.	2.5	2
180	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2022, 107, 774-775.	3.5	2

#	ARTICLE	IF	CITATIONS
181	Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone. <i>Experimental Hematology</i> , 2022, 110, 60-68.	0.4	2
182	Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2022, 101, 1217-1226.	1.8	2
183	Excellent outcomes of hematopoietic stem cell transplantation with total nodal irradiation and antithymocyte globulin conditioning in severe aplastic anemia with advanced age and/or severe comorbidity. <i>Bone Marrow Transplantation</i> , 2020, 55, 1447-1450.	2.4	1
184	Role of pretransplant anti- α CD25 antithymocyte globulin in matched sibling donor stem cell transplantation after reduced intensity conditioning for myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2020, 104, 459-468.	2.2	1
185	Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Supportive Care in Cancer</i> , 2021, 29, 4969-4977.	2.2	1
186	Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. <i>Current Problems in Cancer</i> , 2021, 46, 100788.	2.0	1
187	Osteonecrosis of the Jaw in Multiple Myeloma Patients: Incidence and Characteristics in Korean Patients.. <i>Blood</i> , 2009, 114, 4956-4956.	1.4	1
188	Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy. <i>Oncotarget</i> , 2018, 9, 5823-5833.	1.8	1
189	Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 944-952.	1.7	1
190	A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling. <i>Blood</i> , 2020, 136, 32-32.	1.4	1
191	A rare case of the IgE prozone phenomenon in IgE multiple myeloma. <i>Clinical Biochemistry</i> , 2022, 104, 59-61.	1.9	1
192	Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second. <i>Blood Research</i> , 2022, 57, 76-80.	1.3	1
193	A Case of Systemic Sclerosis Developed after Autologous Hematopoietic Stem Cell Transplantation in the Patient with Multiple Sclerosis. <i>The Korean Journal of Hematology</i> , 2005, 40, 106.	0.7	0
194	Circulating Levels of Adipokines Predict the Occurrence of Acute Graft-versus-host Disease. <i>Immune Network</i> , 2015, 15, 66.	3.6	0
195	Comparison of transplant-specific prognostic scoring systems in haploidentical transplantation for myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2018, 101, 200-207.	2.2	0
196	Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. <i>Current Problems in Cancer</i> , 2021, 46, 100786.	2.0	0
197	IL10-Transduced Mesenchymal Stem Cells Attenuate Experimental Acute Graft-Versus-Host Disease.. <i>Blood</i> , 2005, 106, 5247-5247.	1.4	0
198	Changes in Serum Free Light Chain and Biochemical Markers in Patients with Multiple Myeloma Receiving Bortezomib Treatment.. <i>Blood</i> , 2006, 108, 5028-5028.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation.. Blood, 2010, 116, 4559-4559.	1.4	0
200	MyD88-Dependent Expansion of An Immature GR-1+CD11b+ Population From Donor Bone Marrow Reduces Early Mortality After Allogeneic Hematopoietic Stem Cell Transplantation,. Blood, 2011, 118, 4011-4011.	1.4	0
201	Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration. Blood, 2013, 122, 3201-3201.	1.4	0
202	Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation. Blood, 2013, 122, 5379-5379.	1.4	0
203	Low Frequency of CD161+CD4+ T Cells Correlate with the Occurrence of Infections in Refractory/Relapsed Multiple Myeloma Patients Receiving Lenalidomide Plus Low-Dose Dexamethasone Treatment. Blood, 2016, 128, 5621-5621.	1.4	0
204	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). Blood, 2016, 128, 4445-4445.	1.4	0
205	Specific Donor Human Leukocyte Antigen (HLA) Allotypes and CMV IgG Serology Status Predict the Risk of Cytomegalovirus-Related Disease in Acute Myeloid Leukemia Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 2076-2076.	1.4	0
206	Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia. Blood, 2019, 134, 4619-4619.	1.4	0
207	<i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutations in plasma cell myeloma at a single Korean institute. Blood Research, 2020, 55, 159-168.	1.3	0
208	Haploidentical Versus Cord Blood Stem Cell Transplantation As the Second Transplant for Relapsed Acute Myeloid Leukemia Patients after the First Stem Cell Transplantation. Blood, 2021, 138, 1849-1849.	1.4	0
209	Superior Survival Outcome of Blinatumomab Compared to Mitoxantrone-Etoposide-Cytarabine Salvage for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Propensity Score-Matched Cohort Analysis. Blood, 2021, 138, 2309-2309.	1.4	0
210	Comparison of Prognostic Impact between the European Leukemia Net (ELN) 2017 Risk Classification and Pre-Transplant WT1 expression in Patients Receiving Allogeneic Transplantation for Acute Myeloid Leukemia (AML). Blood, 2021, 138, 3459-3459.	1.4	0
211	The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. Blood, 2020, 136, 30-31.	1.4	0
212	Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients. Blood, 2020, 136, 19-20.	1.4	0
213	Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). International Journal of Hematology, 2022, , 1.	1.6	0